Selected research
Industry Growth & Trends
Global Lipid Nanoparticle (LNP) CDMO Service Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Lipid Nanoparticle (LNP) CDMO Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Lipid Nanoparticle (LNP) CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Lipid Nanoparticle (LNP) CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Lipid Nanoparticle (LNP) CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Lipid Nanoparticle (LNP) CDMO Service market include Evonik, Helix Biotech, FUJIFILM Holdings, Merck, Ascendia Pharmaceuticals, Catalent, Polymun Scientific, Genevant Sciences and Cytiva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Lipid Nanoparticle (LNP) CDMO Service market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Lipid Nanoparticle (LNP) CDMO Service market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Lipid Nanoparticle (LNP) CDMO Service market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Lipid Nanoparticle (LNP) CDMO Service.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Lipid Nanoparticle (LNP) CDMO Service market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Lipid Nanoparticle (LNP) CDMO Service Market by Company
Evonik
Helix Biotech
FUJIFILM Holdings
Merck
Ascendia Pharmaceuticals
Catalent
Polymun Scientific
Genevant Sciences
Cytiva
Croda International
Nippon Fine Chemical
Patheon
Biomay
Pace Analytical
CordenPharma
Vernal Biosciences
Lonza
Acuitas Therapeutics
Creative Biolabs
WuXi STA
GenScript
MicroNano Biologics
Lipid Nanoparticle (LNP) CDMO Service Segment by Type
Formulation Development
cGMP Manufacturing
Others
Lipid Nanoparticle (LNP) CDMO Service Segment by Application
Vaccine Development
Gene Therapy
Drug Delivery
Others
Lipid Nanoparticle (LNP) CDMO Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lipid Nanoparticle (LNP) CDMO Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Lipid Nanoparticle (LNP) CDMO Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lipid Nanoparticle (LNP) CDMO Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Lipid Nanoparticle (LNP) CDMO Service companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Formulation Development
- cGMP Manufacturing
- Others
Applications
- Vaccine Development
- Gene Therapy
- Drug Delivery
- Others
Companies covered
- Evonik
- Helix Biotech
- FUJIFILM Holdings
- Merck
- Ascendia Pharmaceuticals
- Catalent
- Polymun Scientific
- Genevant Sciences
- Cytiva
- Croda International
- Nippon Fine Chemical
- Patheon
- Biomay
- Pace Analytical
- CordenPharma
- Vernal Biosciences
- Lonza
- Acuitas Therapeutics
- Creative Biolabs
- WuXi STA
- GenScript
- MicroNano Biologics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Lipid Nanoparticle (LNP) CDMO Service Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Lipid Nanoparticle (LNP) CDMO Service Market Size by Region (2021-2032)
- 1.4.1 Global Lipid Nanoparticle (LNP) CDMO Service Market Size by Region (2021-2026)
- 1.4.2 Global Lipid Nanoparticle (LNP) CDMO Service Market Size by Region (2027-2032)
- 1.5 Key Regions Lipid Nanoparticle (LNP) CDMO Service Market Size (2021-2032)
- 1.5.1 North America Lipid Nanoparticle (LNP) CDMO Service Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Lipid Nanoparticle (LNP) CDMO Service Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Lipid Nanoparticle (LNP) CDMO Service Market Size Growth Rate (2021-2032)
- 1.5.4 South America Lipid Nanoparticle (LNP) CDMO Service Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Lipid Nanoparticle (LNP) CDMO Service Market Size Growth Rate (2021-2032)
2 Lipid Nanoparticle (LNP) CDMO Service Market by Type
- 2.1 Type Introduction
- 2.1.1 Formulation Development
- 2.1.2 cGMP Manufacturing
- 2.1.3 Others
- 2.2 Global Lipid Nanoparticle (LNP) CDMO Service Market Size by Type
- 2.2.1 Global Lipid Nanoparticle (LNP) CDMO Service Market Size Overview by Type (2021-2032)
- 2.2.2 Global Lipid Nanoparticle (LNP) CDMO Service Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Lipid Nanoparticle (LNP) CDMO Service Market Size Forecasted by Type (2027-2032)
- 2.3 Global Lipid Nanoparticle (LNP) CDMO Service Market Size by Regions
- 2.3.1 North America Lipid Nanoparticle (LNP) CDMO Service Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Lipid Nanoparticle (LNP) CDMO Service Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Lipid Nanoparticle (LNP) CDMO Service Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Lipid Nanoparticle (LNP) CDMO Service Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Lipid Nanoparticle (LNP) CDMO Service Market Size Breakdown by Type (2021-2026)
3 Lipid Nanoparticle (LNP) CDMO Service Market by Application
- 3.1 Type Introduction
- 3.1.1 Vaccine Development
- 3.1.2 Gene Therapy
- 3.1.3 Drug Delivery
- 3.1.4 Others
- 3.2 Global Lipid Nanoparticle (LNP) CDMO Service Market Size by Application
- 3.2.1 Global Lipid Nanoparticle (LNP) CDMO Service Market Size Overview by Application (2021-2032)
- 3.2.2 Global Lipid Nanoparticle (LNP) CDMO Service Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Lipid Nanoparticle (LNP) CDMO Service Market Size Forecasted by Application (2027-2032)
- 3.3 Global Lipid Nanoparticle (LNP) CDMO Service Market Size by Regions
- 3.3.1 North America Lipid Nanoparticle (LNP) CDMO Service Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Lipid Nanoparticle (LNP) CDMO Service Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Lipid Nanoparticle (LNP) CDMO Service Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Lipid Nanoparticle (LNP) CDMO Service Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Lipid Nanoparticle (LNP) CDMO Service Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Lipid Nanoparticle (LNP) CDMO Service Industry Trends
- 4.2 Lipid Nanoparticle (LNP) CDMO Service Industry Drivers
- 4.3 Lipid Nanoparticle (LNP) CDMO Service Industry Opportunities and Challenges
- 4.4 Lipid Nanoparticle (LNP) CDMO Service Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Lipid Nanoparticle (LNP) CDMO Service Revenue (2021-2026)
- 5.2 Global Lipid Nanoparticle (LNP) CDMO Service Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Lipid Nanoparticle (LNP) CDMO Service Key Company Headquarters & Area Served
- 5.4 Global Lipid Nanoparticle (LNP) CDMO Service Company, Product Type & Application
- 5.5 Global Lipid Nanoparticle (LNP) CDMO Service Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Lipid Nanoparticle (LNP) CDMO Service Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Lipid Nanoparticle (LNP) CDMO Service Players Market Share by Revenue in 2025
- 5.6.3 2025 Lipid Nanoparticle (LNP) CDMO Service Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Evonik
- 6.1.1 Evonik Company Information
- 6.1.2 Evonik Business Overview
- 6.1.3 Evonik Lipid Nanoparticle (LNP) CDMO Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Evonik Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
- 6.1.5 Evonik Recent Developments
- 6.2 Helix Biotech
- 6.2.1 Helix Biotech Company Information
- 6.2.2 Helix Biotech Business Overview
- 6.2.3 Helix Biotech Lipid Nanoparticle (LNP) CDMO Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Helix Biotech Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
- 6.2.5 Helix Biotech Recent Developments
- 6.3 FUJIFILM Holdings
- 6.3.1 FUJIFILM Holdings Company Information
- 6.3.2 FUJIFILM Holdings Business Overview
- 6.3.3 FUJIFILM Holdings Lipid Nanoparticle (LNP) CDMO Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 FUJIFILM Holdings Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
- 6.3.5 FUJIFILM Holdings Recent Developments
- 6.4 Merck
- 6.4.1 Merck Company Information
- 6.4.2 Merck Business Overview
- 6.4.3 Merck Lipid Nanoparticle (LNP) CDMO Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Merck Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
- 6.4.5 Merck Recent Developments
- 6.5 Ascendia Pharmaceuticals
- 6.5.1 Ascendia Pharmaceuticals Company Information
- 6.5.2 Ascendia Pharmaceuticals Business Overview
- 6.5.3 Ascendia Pharmaceuticals Lipid Nanoparticle (LNP) CDMO Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Ascendia Pharmaceuticals Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
- 6.5.5 Ascendia Pharmaceuticals Recent Developments
- 6.6 Catalent
- 6.6.1 Catalent Company Information
- 6.6.2 Catalent Business Overview
- 6.6.3 Catalent Lipid Nanoparticle (LNP) CDMO Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Catalent Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
- 6.6.5 Catalent Recent Developments
- 6.7 Polymun Scientific
- 6.7.1 Polymun Scientific Company Information
- 6.7.2 Polymun Scientific Business Overview
- 6.7.3 Polymun Scientific Lipid Nanoparticle (LNP) CDMO Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Polymun Scientific Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
- 6.7.5 Polymun Scientific Recent Developments
- 6.8 Genevant Sciences
- 6.8.1 Genevant Sciences Company Information
- 6.8.2 Genevant Sciences Business Overview
- 6.8.3 Genevant Sciences Lipid Nanoparticle (LNP) CDMO Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Genevant Sciences Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
- 6.8.5 Genevant Sciences Recent Developments
- 6.9 Cytiva
- 6.9.1 Cytiva Company Information
- 6.9.2 Cytiva Business Overview
- 6.9.3 Cytiva Lipid Nanoparticle (LNP) CDMO Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Cytiva Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
- 6.9.5 Cytiva Recent Developments
- 6.10 Croda International
- 6.10.1 Croda International Company Information
- 6.10.2 Croda International Business Overview
- 6.10.3 Croda International Lipid Nanoparticle (LNP) CDMO Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Croda International Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
- 6.10.5 Croda International Recent Developments
- 6.11 Nippon Fine Chemical
- 6.11.1 Nippon Fine Chemical Company Information
- 6.11.2 Nippon Fine Chemical Business Overview
- 6.11.3 Nippon Fine Chemical Lipid Nanoparticle (LNP) CDMO Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Nippon Fine Chemical Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
- 6.11.5 Nippon Fine Chemical Recent Developments
- 6.12 Patheon
- 6.12.1 Patheon Company Information
- 6.12.2 Patheon Business Overview
- 6.12.3 Patheon Lipid Nanoparticle (LNP) CDMO Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Patheon Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
- 6.12.5 Patheon Recent Developments
- 6.13 Biomay
- 6.13.1 Biomay Company Information
- 6.13.2 Biomay Business Overview
- 6.13.3 Biomay Lipid Nanoparticle (LNP) CDMO Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Biomay Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
- 6.13.5 Biomay Recent Developments
- 6.14 Pace Analytical
- 6.14.1 Pace Analytical Company Information
- 6.14.2 Pace Analytical Business Overview
- 6.14.3 Pace Analytical Lipid Nanoparticle (LNP) CDMO Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Pace Analytical Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
- 6.14.5 Pace Analytical Recent Developments
- 6.15 CordenPharma
- 6.15.1 CordenPharma Company Information
- 6.15.2 CordenPharma Business Overview
- 6.15.3 CordenPharma Lipid Nanoparticle (LNP) CDMO Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.15.4 CordenPharma Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
- 6.15.5 CordenPharma Recent Developments
- 6.16 Vernal Biosciences
- 6.16.1 Vernal Biosciences Company Information
- 6.16.2 Vernal Biosciences Business Overview
- 6.16.3 Vernal Biosciences Lipid Nanoparticle (LNP) CDMO Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.16.4 Vernal Biosciences Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
- 6.16.5 Vernal Biosciences Recent Developments
- 6.17 Lonza
- 6.17.1 Lonza Company Information
- 6.17.2 Lonza Business Overview
- 6.17.3 Lonza Lipid Nanoparticle (LNP) CDMO Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.17.4 Lonza Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
- 6.17.5 Lonza Recent Developments
- 6.18 Acuitas Therapeutics
- 6.18.1 Acuitas Therapeutics Company Information
- 6.18.2 Acuitas Therapeutics Business Overview
- 6.18.3 Acuitas Therapeutics Lipid Nanoparticle (LNP) CDMO Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.18.4 Acuitas Therapeutics Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
- 6.18.5 Acuitas Therapeutics Recent Developments
- 6.19 Creative Biolabs
- 6.19.1 Creative Biolabs Company Information
- 6.19.2 Creative Biolabs Business Overview
- 6.19.3 Creative Biolabs Lipid Nanoparticle (LNP) CDMO Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.19.4 Creative Biolabs Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
- 6.19.5 Creative Biolabs Recent Developments
- 6.20 WuXi STA
- 6.20.1 WuXi STA Company Information
- 6.20.2 WuXi STA Business Overview
- 6.20.3 WuXi STA Lipid Nanoparticle (LNP) CDMO Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.20.4 WuXi STA Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
- 6.20.5 WuXi STA Recent Developments
- 6.21 GenScript
- 6.21.1 GenScript Company Information
- 6.21.2 GenScript Business Overview
- 6.21.3 GenScript Lipid Nanoparticle (LNP) CDMO Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.21.4 GenScript Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
- 6.21.5 GenScript Recent Developments
- 6.22 MicroNano Biologics
- 6.22.1 MicroNano Biologics Company Information
- 6.22.2 MicroNano Biologics Business Overview
- 6.22.3 MicroNano Biologics Lipid Nanoparticle (LNP) CDMO Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.22.4 MicroNano Biologics Lipid Nanoparticle (LNP) CDMO Service Product Portfolio
- 6.22.5 MicroNano Biologics Recent Developments
7 North America
- 7.1 North America Lipid Nanoparticle (LNP) CDMO Service Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Lipid Nanoparticle (LNP) CDMO Service Market Size by Country (2021-2026)
- 7.3 North America Lipid Nanoparticle (LNP) CDMO Service Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Lipid Nanoparticle (LNP) CDMO Service Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Lipid Nanoparticle (LNP) CDMO Service Market Size by Country (2021-2026)
- 8.3 Europe Lipid Nanoparticle (LNP) CDMO Service Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Lipid Nanoparticle (LNP) CDMO Service Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Lipid Nanoparticle (LNP) CDMO Service Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Lipid Nanoparticle (LNP) CDMO Service Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Lipid Nanoparticle (LNP) CDMO Service Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Lipid Nanoparticle (LNP) CDMO Service Market Size by Country (2021-2026)
- 10.3 South America Lipid Nanoparticle (LNP) CDMO Service Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Lipid Nanoparticle (LNP) CDMO Service Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Lipid Nanoparticle (LNP) CDMO Service Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Lipid Nanoparticle (LNP) CDMO Service Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst